



SINGAPORE MEDICAL GROUP LIMITED (Co. Reg. No.: 200503187W)

FULL YEAR FINANCIAL STATEMENT AND DIVIDEND ANNOUNCEMENT

PART 1 - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income for the group together with a comparative statement for the corresponding period of the immediately preceding financial year

CONSOLIDATED INCOME STATEMENT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019

	Fourth quarter			Year ended		
	<u>31/12/2019</u>	<u>31/12/2018</u>	<u>Increase/ (decrease)</u>	<u>31/12/2019</u>	<u>31/12/2018</u>	<u>Increase/ (decrease)</u>
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Revenue	25,856	22,193	16.5	94,672	85,069	11.3
Cost of sales	(14,366)	(12,563)	14.4	(51,431)	(47,274)	8.8
Gross profit	11,490	9,630	19.3	43,241	37,795	14.4
Financial income	34	28	21.4	100	71	40.8
Other income	45	83	(45.8)	104	275	(62.2)
Other gains	29	-	100.0	29	167	(82.6)
Distribution and selling expenses	(1,168)	(947)	23.3	(4,142)	(3,618)	14.5
Administrative expenses	(6,241)	(5,651)	10.4	(22,132)	(19,542)	13.3
Financial expenses	(243)	(290)	(16.2)	(1,404)	(1,100)	27.6
Share of results of joint ventures and associate	327	(49)	N.M.	273	56	387.5
Profit before tax	4,273	2,804	52.4	16,069	14,104	13.9
Income tax (expense)/credit	(663)	132	N.M.	(2,434)	(1,189)	104.7
Profit for the period/year	3,610	2,936	23.0	13,635	12,915	5.6
Other comprehensive income						
Items that may be reclassified subsequently to profit or loss:						
Foreign currency translation	83	(150)	N.M.	(3)	(530)	(99.4)
Total comprehensive income for the period/year	3,693	2,786	32.6	13,632	12,385	10.1
Profit attributable to:						
Owners of the Company	3,683	2,944	25.1	13,661	12,928	5.7
Non-controlling interests	(73)	(8)	812.5	(26)	(13)	100.0
	3,610	2,936	23.0	13,635	12,915	5.6
Total comprehensive income attributable to:						
Owners of the Company	3,766	2,794	34.8	13,658	12,398	10.2
Non-controlling interests	(73)	(8)	812.5	(26)	(13)	100.0
	3,693	2,786	32.6	13,632	12,385	10.1

N.M.: Not meaningful

Notes to the Consolidated Statement of Comprehensive Income

The profit before tax is determined after charging/(crediting) the following:

	Fourth quarter			Year ended		
	31/12/2019	31/12/2018	Increase/ (decrease)	31/12/2019	31/12/2018	Increase/ (decrease)
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Depreciation of property, plant and equipment	521	915	(43.1)	3,009	3,882	(22.5)
Depreciation of right-of-use assets ¹	1,739	-	100.0	5,924	-	100.0
Amortisation of intangible assets	84	80	5.0	245	80	206.3
Expenses relating to short-term leases	23	-	100.0	309	-	100.0
Accretion of interest on lease liabilities	64	-	100.0	310	-	100.0
Operating lease expenses	-	1,472	(100.0)	-	5,313	(100.0)
Personnel expenses	9,152	7,683	19.1	31,476	29,673	6.1
Share-based compensation expense, included under personnel expenses	75	152	(50.7)	390	324	20.4
Loss/(Gain) on disposal of property, plant and equipment	3	1	200.0	(12)	(23)	(47.8)
Reversal of impairment loss on investment in joint venture	-	-	-	-	(167)	(100.0)
Gain on dilution of interest in joint ventures	(29)	-	100.0	(29)	-	100.0
Impairment loss on trade receivables	147	67	119.4	147	67	119.4
Under/(Over) provision of income tax in respect of prior years	168	(543)	N.M.	183	(537)	N.M.

¹ As disclosed in paragraph 5 of this announcement, the Group has adopted SFRS(I) 16 resulting in: (i) the recognition of right-of-use assets for leased premises (previously classified as operating leases); and (ii) the reclassification of medical equipment under hire purchase from property, plant and equipment to right-of-use assets. Depreciation of right-of-use assets comprises depreciation relating to leased premises of S\$5,052,000 (included in under cost of sales) and those relating to medical equipment of S\$872,000 (included in administrative expenses). Depreciation of right-of-use assets relating to medical equipment were recorded under depreciation of property, plant and equipment in 2018.

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

	<u>Group</u>		<u>Company</u>	
	31/12/2019	31/12/2018	31/12/2019	31/12/2018
	S\$'000	S\$'000	S\$'000	S\$'000
ASSETS				
Non-current assets				
Property, plant and equipment	7,742	13,652	1,102	2,365
Intangible assets	126,921	126,543	238	19
Right-of-use assets ²	13,276	-	4,103	-
Investment in subsidiaries	-	-	125,085	113,664
Investment in joint ventures	1,749	1,642	2,151	2,541
Investment in associates	5,868	5,714	6,395	6,045
Other investment	1,285	-	1,285	-
Other receivables	2,906	2,900	758	1,288
Deferred tax assets	754	844	286	170
	<u>160,501</u>	<u>151,295</u>	<u>141,403</u>	<u>126,092</u>
Current assets				
Inventories	1,800	1,694	-	-
Trade receivables	5,631	6,031	-	-
Prepayments	982	1,775	150	352
Other receivables	1,657	1,037	267	93
Due from related companies	-	-	11,312	8,525
Cash and cash equivalents	27,316	20,012	12,159	6,071
	<u>37,386</u>	<u>30,549</u>	<u>23,888</u>	<u>15,041</u>
Total assets	<u>197,887</u>	<u>181,844</u>	<u>165,291</u>	<u>141,133</u>
EQUITY AND LIABILITIES				
Current liabilities				
Trade payables	2,120	1,648	2	2
Other payables and accruals	12,223	10,310	1,015	993
Contract liabilities	1,986	2,313	-	-
Deferred purchase consideration	1,377	15,538	-	1,000
Due to related companies	-	-	8,972	-
Lease liabilities ²	5,880	1,446	2,556	281
Convertible loan	9,201	-	9,201	-
Loans and borrowings	5,709	4,773	1,000	216
Income tax payable	2,174	1,776	-	-
	<u>40,670</u>	<u>37,804</u>	<u>22,746</u>	<u>2,492</u>
Net current (liabilities)/assets	<u>(3,284)</u>	<u>(7,255)</u>	<u>1,142</u>	<u>12,549</u>
Non-current liabilities				
Other payables and accruals	379	503	211	85
Deferred purchase consideration	-	1,335	-	-
Due to related companies	-	-	7,783	16,274
Lease liabilities ²	6,066	1,724	1,297	364
Loans and borrowings	5,295	9,980	-	-
Deferred tax liabilities	228	170	-	-
	<u>11,968</u>	<u>13,712</u>	<u>9,291</u>	<u>16,723</u>
Total liabilities	<u>52,638</u>	<u>51,516</u>	<u>32,037</u>	<u>19,215</u>
Net assets	<u>145,249</u>	<u>130,328</u>	<u>133,254</u>	<u>121,918</u>

² As disclosed in paragraph 5 of this announcement, the Group has adopted SFRS(I) 16 resulting in: (i) the recognition of right-of-use assets, lease receivable (which is included under other receivables) and lease liabilities of S\$13.2 million, S\$0.3 million and S\$13.3 million respectively for its leases previously classified as operating leases; and (ii) the reclassification of assets under finance leases of S\$4.7 million from property, plant and equipment to right-of-use assets, as of 1 January 2019.

	<u>Group</u>		<u>Company</u>	
	31/12/2019	31/12/2018	31/12/2019	31/12/2018
	S\$'000	S\$'000	S\$'000	S\$'000
Equity attributable to owners of the Company				
Share capital	119,789	118,918	119,789	118,918
Treasury shares	(42)	-	(42)	-
Share option reserve	680	443	680	443
Equity component of convertible loan	603	-	603	-
Foreign currency translation reserve	(645)	(642)	-	-
Retained earnings	25,566	12,059	12,224	2,557
	145,951	130,778	133,254	121,918
Non-controlling interests	(702)	(450)	-	-
Total equity	145,249	130,328	133,254	121,918
Total equity and liabilities	197,887	181,844	165,291	141,133

1(b)(ii) Aggregate amount of group's borrowings and debt securities

Amount repayable in one year or less, or on demand

At 31/12/2019		At 31/12/2018	
Secured	Unsecured	Secured	Unsecured
S\$'000	S\$'000	S\$'000	S\$'000
5,905	10,201	4,996	1,223

Amount repayable after one year

At 31/12/2019		At 31/12/2018	
Secured	Unsecured	Secured	Unsecured
S\$'000	S\$'000	S\$'000	S\$'000
6,114	-	10,082	1,622

Details of any collateral

Loans and borrowings

Loans and borrowings amounting to:

- (a) S\$8,383,000 (31/12/2018: S\$11,908,000) are secured by: (i) a charge over the share capital of 8 wholly-owned subsidiaries; (ii) an assignment of the sale and purchase agreements and the Deed of Profit Guarantee in relation to the Astra Companies³; (iii) a first fixed charge over the consultancy agreements of certain doctors of the Group; (iv) a fixed and floating charge on all assets of the Astra Companies; and (v) corporate guarantee taken by 2 subsidiaries of the Group; and
- (b) S\$1,621,000 (31/12/2018: S\$2,629,000) are secured by corporate guarantee taken by the Company.

³ Astra Companies comprise Astra Women's Specialists (WB) Pte. Ltd., The Women's Specialist Centre (HC) Pte. Ltd., Fong's Clinic (TB) Pte. Ltd., Astra Centre for Women & Fertility Pte. Ltd., Astra Women's Specialists (JL) Pte. Ltd., TCK@Novena Pte. Ltd. and Alpha Healthcare International Pte. Ltd.

Hire purchase of medical equipment

Included in lease liabilities are hire purchases of medical equipment amounting to S\$2,015,000 (31/12/2018: S\$3,170,000) that are secured by the Group's medical equipment with carrying amount of approximately S\$3,742,000 (31/12/2018: S\$4,695,000).

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year

	<u>Fourth quarter</u>		<u>Year ended</u>	
	<u>31/12/2019</u>	<u>31/12/2018</u>	<u>31/12/2019</u>	<u>31/12/2018</u>
	<u>S\$'000</u>	<u>S\$'000</u>	<u>S\$'000</u>	<u>S\$'000</u>
Profit before tax	4,273	2,804	16,069	14,104
<u>Adjustments for:</u>				
Depreciation of property, plant and equipment	521	915	3,009	3,882
Depreciation of right-of-use assets	1,739	-	5,924	-
Amortisation of intangible assets	84	80	245	80
Interest income	(31)	(28)	(91)	(71)
Accretion of interest on lease receivable	(3)	-	(9)	-
Interest expense	155	223	934	798
Amortisation of loan costs	11	11	45	45
Accretion of interest on deferred purchase consideration	13	56	115	257
Accretion of interest on lease liabilities	64	-	310	-
Loss/(Gain) on disposal of property, plant and equipment	3	1	(12)	(23)
Reversal of impairment loss on investment in joint venture	-	-	-	(167)
Gain on dilution of interest in joint venture	(29)	-	(29)	-
Impairment loss on trade receivables	146	67	147	67
Share-based compensation expense	75	152	390	324
Share of results of joint ventures and associates	(327)	49	(273)	(56)
Total adjustments	2,421	1,526	10,705	5,136
Operating profit before working capital change	6,694	4,330	26,774	19,240
<u>Change in working capital</u>				
Decrease/(increase) in:				
Inventories	8	125	(107)	(68)
Trade and other receivables	(401)	4	(280)	(887)
Prepayments	271	(350)	796	(493)
(Decrease)/increase in:				
Trade payables	(70)	(213)	470	(199)
Other payables and accruals	2,257	2,772	886	827
Total change in working capital	2,065	2,338	1,765	(820)
Cash flow generated from operations	8,759	6,668	28,539	18,420
Interest received	28	28	88	71
Interest paid	(260)	(187)	(1,003)	(760)
Income taxes (paid)/refunded	(313)	223	(1,888)	(924)
Net cash flows generated from operating activities	8,214	6,732	25,736	16,807
Cash flows from investing activities				
Purchase of property, plant and equipment	(348)	(504)	(1,521)	(2,899)
Purchase of intangible assets	(295)	(8)	(623)	(522)
Proceeds from sale of property, plant and equipment	-	-	-	60
Net cash outflow on acquisition of subsidiaries	(1,106)	(1,705)	(15,611)	(18,070)
Investment in associate	-	(226)	-	(5,592)
Return of capital by a joint venture	213	-	213	-
Loan to associate	-	-	(300)	-
Loans to a joint venture	(133)	(720)	(653)	(1,026)
Proceeds from repayment of loan to a joint venture	-	-	103	-
Other investment	-	-	(354)	-
Net cash flows used in investing activities	(1,669)	(3,163)	(18,746)	(28,049)

	<u>Fourth quarter</u>		<u>Year ended</u>	
	<u>31/12/2019</u>	<u>31/12/2018</u>	<u>31/12/2019</u>	<u>31/12/2018</u>
	<u>S\$'000</u>	<u>S\$'000</u>	<u>S\$'000</u>	<u>S\$'000</u>
Cash flows from financing activities				
Dividend paid to non-controlling interests	-	(250)	(380)	(250)
Proceeds from issuance of shares	-	-	718	7,088
Share issuance expenses	-	-	-	(312)
Purchase of treasury shares	(42)	-	(42)	-
Proceeds from convertible loan	-	-	9,804	-
Proceeds from loans and borrowings	-	-	3,000	10,600
Repayment of loans and borrowings	(2,257)	(1,233)	(6,867)	(5,608)
Principal element of lease payments	(1,626)	(386)	(5,919)	(1,590)
Deposit pledged for bank facility	-	25	-	25
Net cash flows (used in)/generated from financing activities	(3,925)	(1,844)	314	9,953
Net increase/(decrease) in cash and cash equivalents	2,620	1,725	7,304	(1,289)
Cash and cash equivalents at the beginning of financial period/year	24,696	18,287	20,012	21,301
Cash and cash equivalents at the end of financial period/year	27,316	20,012	27,316	20,012

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

GROUP	Attributable to owners of the Company						Non-controlling interests	Total equity	
	Share capital	Treasury shares	Share option reserve	Equity component of convertible loan	Foreign currency translation reserve	Retained earnings/ (accumulated losses)			Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000			S\$'000
At 1 January 2019	118,918	-	443	-	(642)	12,059	130,778	(450)	130,328
Profit for the year	-	-	-	-	-	13,661	13,661	(26)	13,635
Foreign currency translation differences	-	-	-	-	(3)	-	(3)	-	(3)
Total comprehensive income for the year	-	-	-	-	(3)	13,661	13,658	(26)	13,632
Issuance of shares	871	-	(153)	-	-	-	718	-	718
Purchase of treasury shares	-	(42)	-	-	-	-	(42)	-	(42)
Share-based compensation expense	-	-	390	-	-	-	390	-	390
Dividends on ordinary shares	-	-	-	-	-	-	-	(380)	(380)
Issuance of convertible loan	-	-	-	603	-	-	603	-	603
Acquisition of non-controlling interests without a change in control	-	-	-	-	-	(154)	(154)	154	-
At 31 December 2019	119,789	(42)	680	603	(645)	25,566	145,951	(702)	145,249
At 1 January 2018	108,738	-	526	-	(112)	(869)	108,283	50	108,333
Profit for the year	-	-	-	-	-	12,928	12,928	(13)	12,915
Foreign currency translation differences	-	-	-	-	(530)	-	(530)	-	(530)
Total comprehensive income for the year	-	-	-	-	(530)	12,928	12,398	(13)	12,385
Issuance of shares	7,495	-	(407)	-	-	-	7,088	-	7,088
Share issuance expenses	(312)	-	-	-	-	-	(312)	-	(312)
Share-based compensation expense	-	-	324	-	-	-	324	-	324
Dividend on ordinary shares	-	-	-	-	-	-	-	(250)	(250)
Acquisition of subsidiary	2,997	-	-	-	-	-	2,997	(237)	2,760
At 31 December 2019	118,918	-	443	-	(642)	12,059	130,778	(450)	130,328

<u>Company</u>	Share capital	Treasury shares	Share option reserve	Equity component of convertible loan	Retained earnings/ (accumulated losses)	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
At 31 December 2018, as previously reported	118,918	-	443	-	2,557	121,918
Effects of adoption SFRS(l) 16	-	-	-	-	(96)	(96)
At 1 January 2019	118,918	-	443	-	2,461	121,822
Total comprehensive income for the year	-	-	-	-	9,763	9,763
Issuance of shares	871	-	(153)	-	-	718
Purchase of treasury shares	-	(42)	-	-	-	(42)
Share-based compensation expense	-	-	390	-	-	390
Issuance of convertible loan	-	-	-	603	-	603
At 31 December 2019	119,789	(42)	680	603	12,224	133,254
At 1 January 2018	108,738	-	526	-	(6,285)	102,979
Total comprehensive income for the year	-	-	-	-	8,842	8,842
Issuance of shares	7,495	-	(407)	-	-	7,088
Share issuance expenses	(312)	-	-	-	-	(312)
Share-based compensation expense	-	-	324	-	-	324
Acquisition of subsidiary	2,997	-	-	-	-	2,997
At 31 December 2018	118,918	-	443	-	2,557	121,918

1(d)(ii) Details of any changes in the company’s share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Share capital

	2019		2018	
	No. of shares '000	S\$'000	No. of shares '000	S\$'000
<u>Issued and fully paid ordinary shares</u>				
At 1 October	483,021	119,789	480,652	118,511
Reclassification from share option reserve for share options exercised by employees	-	-	-	407
At 31 December	483,021	119,789	480,652	118,918

Share Option

The SMG Share Option Scheme (“**SSOS**”) was approved by the shareholders at the Extraordinary General Meeting on 30 April 2014. During the fourth quarter ended 31 December 2019, no share options (Fourth quarter ended 31/12/2018: Nil) were granted to employees under the SSOS. As at 31 December 2019, the number of shares that may be issued on conversion of all the outstanding share options were 10,350,000 (31/12/2018: 10,875,000).

The movement of share options of the Company during the financial period from October to December 2019 is as follows:

Date of grant of options	Exercise price per share	Options outstanding at 01/10/2019	Options granted	Options exercised	Options forfeited/expired	Options outstanding at 31/12/2019	Expiry date
22/09/2016	S\$0.303	2,510,000	-	-	-	2,510,000	21/09/2021
03/04/2017	S\$0.545	585,000	-	-	-	585,000	02/04/2022
30/04/2018	S\$0.493	5,320,000	-	-	-	5,320,000	29/04/2023
31/05/2019	S\$0.393	1,935,000	-	-	-	1,935,000	30/05/2024
		<u>10,350,000</u>	-	-	-	<u>10,350,000</u>	

Performance Share Plan

In addition to the SSOS, share awards can be granted to employees under the SMG Performance Share Plan (“**SPSP**”), which was approved by the shareholders at the Extraordinary General Meeting on 30 April 2014.

Depending on the achievement of pre-determined targets over the performance periods for the SPSP, the final number of performance shares awarded will be adjusted accordingly.

During the fourth quarter ended 31 December 2019, no performance shares (Fourth quarter ended 31/12/2018: Nil) were granted to employees under the SPSP. As at 31 December 2019, the number of outstanding performance shares granted under the SPSP were 336,000 (31/12/2018: 336,000).

The details of the shares granted under SPSP are as follows:

Date of grant	Number of Performance Shares				Outstanding at 31/12/2019
	Outstanding at 01/10/2019	Granted	Adjustments [#]	Vested	
30/04/2018	336,000	-	-	-	336,000
	336,000	-	-	-	336,000

[#] Adjustment will be made at the end of each performance period upon meeting pre-determined performance targets by multiplying the higher of: (i) accumulated dividend yield; or (ii) 3% per annum on a compounded basis for the respective performance period.

Convertible Loan

The Company had, on 25 April 2019, obtained shareholders' approval for the issuance of an aggregate of up to 23,640,662 new ordinary shares in the capital of the Company to CHA Healthcare Singapore Pte. Ltd. ("CHS"), upon the conversion of the convertible loan of S\$10.0 million (the "Convertible Loan") pursuant to the terms and conditions of a convertible loan agreement dated 20 February 2019. The Company had drawn down the Convertible Loan and released the announcement via SGXNET on 4 June 2019.

Save as disclosed above, there were no other outstanding options and convertibles as at 31 December 2019 and 31 December 2018.

Treasury Shares

	2019		2018	
	No. of shares	S\$	No. of shares	S\$
At 1 October	-	-	-	-
Purchase of treasury shares	139,000	42,004	-	-
At 31 December	139,000	42,004	-	-

There were no subsidiary holdings held by the Company as at 31 December 2019 and 31 December 2018.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

	As at 31/12/2019	As at 31/12/2018
Total number of issued shares	483,021,635	480,651,635
Treasury shares	(139,000)	-
Total number of issued shares (excluding treasury shares)	482,882,635	480,651,635

As at 24 February 2020, the number of issued shares (excluding treasury shares) is 482,882,635.

1(d)(iv) A statement showing all sales, transfer, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Please refer to paragraph 1(d)(ii) for movements in treasury shares.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable as the Company did not hold any subsidiary holdings as at 31 December 2019 and 31 December 2018.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice

The figures have not been audited or reviewed by the Company's auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter)

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited financial statements have been applied

Except as disclosed in paragraph 5, the accounting policies and methods of computation have been consistently applied by the Group and the Company and are consistent with the audited financial statements for the financial year ended 31 December 2018.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

The Group has adopted all the applicable new and revised Singapore Financial Reporting Standards (International) ("**SFRS(I)**") and SFRS(I) Interpretations ("**SFRS(I) INT**") which became effective for the accounting periods beginning on or after 1 January 2019. Except for the adoption of SFRS(I) 16 *Leases*, the adoption of the other new and revised SFRS(I) and SFRS(I) INT are currently assessed to have no material financial impact on the Group's financial statements for the current financial period reported on.

Adoption of SFRS(I) 16 *Leases*

SFRS(I) 16 *Leases* introduces a single, on-balance sheet lease accounting model for lessees where the distinction between operating and finance leases is removed. It requires a lessee to recognise a right-of-use ("**ROU**") asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. The accounting for lessors has not changed significantly.

The Group adopted SFRS(I) 16 on 1 January 2019, using the modified retrospective approach, where comparative amounts for the year prior to first adoption will not be restated.

The Group applied the practical expedient to recognise amounts of ROU assets equal to its lease liabilities on 1 January 2019 and recognition exemptions for short-term leases and leases of low value items in accordance with SFRS(I) 16. Subsequent to initial recognition, ROU assets are carried at cost less accumulated depreciation and any accumulated impairment losses while the carrying amount of lease liabilities will take into account interest on the lease liabilities, lease payments made and any reassessment or lease modifications.

The adoption of SFRS(I) 16 resulted in the Group: (i) recognising ROU assets, lease receivable (which is included under other receivables) and lease liabilities of S\$13.2 million, S\$0.3 million and S\$13.5 million respectively for its leases previously classified as operating leases; and (ii) reclassifying assets under finance leases of S\$4.9 million from property, plant and equipment to ROU assets, as of 1 January 2019. It also resulted in a charge to the statement of comprehensive income with the effect of reducing the profit for the current financial year by S\$0.2 million.

6. **Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends:-**
(a) based on the weighted average number of ordinary shares on issue; and
(b) on a fully diluted basis (detailing any adjustments made to the earnings).

	Fourth quarter		Year ended	
	31/12/2019	31/12/2018	31/12/2019	31/12/2018
Net profit attributable to the owners of the Company used in the computation of basic earnings per share (S\$'000)	3,683	2,944	13,661	12,928
Net profit attributable to the owners of the Company used in the computation of diluted earnings per share (S\$'000)	3,757	2,944	13,830	12,928
Earnings per share (cents per share)				
- Basic	0.76	0.61	2.83	2.74
- Diluted	0.74	0.61	2.72	2.74

The basic earnings per share for the fourth quarter and year ended 31 December 2019 is calculated by dividing the net profit for the period attributable to owners of the Company by the weighted average number of ordinary shares in issue of 483,021,635 and 482,093,881 (Fourth quarter and year ended 31 December 2018: 480,651,635 and 471,076,458) respectively. The diluted earnings per share for the fourth quarter and year ended 31 December 2019 is calculated by dividing the net profit for the period attributable to owners of the Company adjusted for interest expense on the Convertible Loan by the weighted average number of ordinary shares in issue of 509,172,297 and 508,534,160 (Fourth quarter and year ended 31 December 2018: 481,374,092 and 472,418,590) respectively. The weighted average number of ordinary shares for diluted earnings per share computation has taken into consideration the share options granted to the employees under the existing employee share option plan and the conversion of the Convertible Loan.

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the (a) current financial period reported on and (b) immediately preceding financial year**

	Group		Company	
	31/12/2019	31/12/2018	31/12/2019	31/12/2018
Net asset value per ordinary share (cents)	30.22	27.21	27.60	25.37

Net asset value per ordinary share is calculated based on 482,882,635 and 480,651,635 ordinary shares (excluding treasury shares) outstanding as at 31 December 2019 and 31 December 2018 respectively.

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, asset or liabilities of the group during the current financial period reported on**

Income statement

Revenue

The Group's revenue increased by 16.5% from S\$22.2 million for the three-month financial period ended 31 December 2018 ("4Q2018") to S\$25.9 million for the three-month period ended 31 December 2019 ("4Q2019"). The increase was due to increase in revenue of Health Business segment and Diagnostic & Aesthetics Business segment by S\$1.9 million and S\$1.8 million respectively mainly arising from the organic growth of the existing clinics.

For the financial year ended 31 December 2019 ("FY2019"), the Group's revenue increased by 11.3% from S\$85.1 million for the financial year ended 31 December 2018 ("FY2018") to S\$94.7 million. The increase was mainly due to:

- (a) Increase in revenue of Diagnostic & Aesthetics Business segment by S\$6.9 million mainly contributed by the subsidiary, Pheniks Pte. Ltd., which was acquired in April 2018; and
- (b) Increase in revenue of Health Business segment by S\$2.7 million mainly due the organic growth of the existing clinics, offset by the decrease in revenue from the closure of the Orthopaedic clinic as the Group restructures its non-core business to avoid competition with the imaging business.

Gross profit

Gross profit increased by 19.3% from S\$9.6 million for 4Q2018 to S\$11.5 million for 4Q2019 as a result of increase in revenue. Gross profit margin increased by one percentage point from 43% in 4Q2018 to 44% in 4Q2019 mainly due to the change in sales mix of the Health Business segment and Diagnostic & Aesthetics Business segment.

For FY2019, gross profit increased by 14.4% from S\$37.8 million for FY2018 to S\$43.2 million while gross profit margin increased by two percentage point from 44% in FY2018 to 46% in FY2019. The increase was mainly due to the same reason as mentioned above.

Other income

Other income decreased by 45.8% from S\$83,000 for 4Q2018 to S\$45,000 for 4Q2019 mainly due to lower miscellaneous income such as government grants.

For FY2019, other income decreased by 62.2% to S\$104,000. The decrease was mainly due to the same reason as mentioned above.

Other gains

Other gains for 4Q2019 comprise gain on dilution of interest in joint venture while there were no other gains for 4Q2018.

Other gains for FY2019 comprise gain on dilution of interest in joint venture while other gains for FY2018 comprise reversal of impairment loss on investment in joint venture.

Distribution and selling expenses

Distribution and selling expenses increased by 23.3% from S\$0.9 million for 4Q2018 to S\$1.2 million for 4Q2019 mainly driven by increase in revenue and increase in marketing expenses incurred by the aesthetics business.

For FY2019, distribution and selling expenses increased by 14.5% from S\$3.6 million for FY2018 to S\$4.1 million. The increase was mainly due to the same reasons as mentioned above.

Administrative expenses

Administrative expenses increased by 10.4% from S\$5.7 million for 4Q2018 to S\$6.2 million for 4Q2019. This was mainly due to increase in staff headcount arising from the increase in the number of clinics and increase in maintenance costs for medical equipment following the expiry of warranty period for certain equipment.

For FY2019, administrative expenses increased by 13.3% from S\$19.5 million for FY2018 to S\$22.1 million. The increase was mainly due to the same reasons as mentioned above.

Financial expenses

Financial expenses decreased by 16.2% from S\$290,000 for 4Q2018 to S\$243,000 for 4Q2019 mainly due to lower accretion of interest on deferred purchase consideration, offset by higher interest expenses incurred on bank loans, which were obtained for paying the cash consideration for the acquisition of the Astra Companies and Kids Clinics⁴, and accretion of interest on lease liabilities arising from the adoption of SFRS(I) 16.

For FY2019, financial expenses increased by 27.6% from S\$1.1 million for FY2018 to S\$1.4 million. The increase was mainly due to higher interest expenses incurred on bank loans and accretion of interest on lease liabilities arising from the adoption of SFRS(I) 16, offset by lower accretion of interest on deferred purchase consideration.

⁴ Kids Clinics comprise Children's Clinic Central Pte. Ltd. and Kids Clinic @ Bishan Pte. Ltd.

Share of results of joint ventures and associate

The Group has share of profit of joint ventures and associates of S\$327,000 for 4Q2019 compared to share of loss of joint ventures and associates of S\$49,000 for 4Q2018. This is mainly due to improvement in financial performance of joint venture entities, PT Ciputra SMG ("**PTCS**") and SMG International (Vietnam) Pte. Ltd. ("**SIV**"), offset by losses incurred by the associated company, CHA SMG (Australia) Pte. Ltd. ("**CSA**").

For FY2019, share of profit of joint ventures and associates increased by 387.5% from S\$56,000 for FY2018 to S\$273,000. The reason for the increase is the same as mentioned above.

Income tax (expense)/credit

The Group has income tax expense of S\$0.7 million for 4Q2019 compared to income tax credit of S\$0.1 million for 4Q2018. This is due to: (i) a higher tax payable resulting from a lower tax exemption on taxable income which is effective for the current financial year; (ii) lesser carried forward tax benefits; and (iii) recognition of additional under provision of prior years' income tax of S\$0.2 million in the current financial period.

For FY2019, income tax expense increased by 104.7% from S\$1.2 million for FY2018 to S\$2.4 million. This is mainly due to a higher tax payable resulting from a lower tax exemption on taxable income which is effective for the current financial year and lesser carried forward tax benefits.

Statement of Financial Position

Non-current assets increased by S\$9.2 million from S\$151.3 million as at 31 December 2018 to S\$160.5 million as at 31 December 2019, mainly due to:

- (a) Increase in intangible assets arising from additions of computer software including the telemedicine platform which was launched in January 2019, offset by amortisation charged for the financial year;
- (b) Recognition of ROU assets and lease receivable (included under non-current other receivables) and reclassification of assets under finance leases from property, plant and equipment to ROU assets arising from the adoption of SFRS(I) 16;
- (c) Increase in investment in joint ventures due to net share of profit of joint ventures for the financial year, offset by the repayment of shareholder's loan and return of capital by PTCS;
- (d) Increase in investment in associates arising from an additional shareholder's loan given to CSA in July 2019, offset by the net share of loss of associates for the financial year; and
- (e) Increase in other investment arising from: (i) conversion of convertible loan given to CityClinic Asia Investments Pte. Ltd. ("CCAI") into ordinary shares; and (ii) purchase of additional shares in CCAI, during the financial year.

The above increase were offset by:

- (a) Decrease in property, plant and equipment arising from: (i) reclassification of assets under finance leases to ROU assets arising from the adoption of SFRS(I) 16; and (ii) depreciation charged for the financial year, offset by additions of assets during the financial year; and
- (c) Decrease in deferred tax assets arising from the utilisation of the carried forward tax benefits.

Current assets increased by S\$6.8 million from S\$30.6 million as at 31 December 2018 to S\$37.4 million as at 31 December 2019, mainly due to increase in cash and cash equivalents, inventories and other receivables of S\$7.3 million, S\$0.1 million and S\$0.6 million respectively, offset by decrease in trade receivables and prepayments of S\$0.4 million and S\$0.8 million respectively.

Current liabilities increased by S\$2.9 million from S\$37.8 million as at 31 December 2018 to S\$40.7 million as at 31 December 2019, mainly due to: (a) increase in trade payables of S\$0.5 million; (b) increase in other payables and accruals of S\$1.9 million; (c) increase in the current portion of lease liabilities of S\$4.4 million mainly arising from recognition of new lease liabilities, which were previously classified as operating leases, on the adoption of SFRS(I) 16; (d) the drawdown of the convertible loan facility offered by CHS where the liability component of the Convertible Loan is S\$9.2 million; (e) increase in the current portion of loans and borrowings of S\$1.0 million arising mainly from new short-term bank loans obtained during the financial year; and (f) increase in current tax payable of S\$0.4 million. The increase is offset by decrease in the current portion of the deferred purchase consideration of S\$14.2 million arising from the payment of deferred consideration, and decrease in contract liabilities of S\$0.3 million.

Non-current liabilities decreased by S\$1.7 million from S\$13.7 million as at 31 December 2018 to S\$12.0 million as at 31 December 2019, mainly due to: (a) decrease in non-current other payables and accruals; and (b) decrease in the non-current portion of loans and borrowings, and deferred purchase consideration as a result of reclassification from non-current to current during the financial year. The decrease is offset by increase in lease liabilities for the same reason as mentioned above and increase in deferred tax liabilities.

Please refer to paragraph 1(d)(ii) for details of increase in share capital.

The Group has net current liabilities of S\$3.3 million (31/12/2018: S\$7.3 million) as at 31 December 2019 mainly due to the recognition of lease liabilities of S\$4.7 million arising from the adoption of SFRS(I) 16 and deferred purchase consideration of S\$1.4 million, which are expected to be paid within 12 months after the balance sheet date. Based on the Group's projected operating cash flows and with existing debt facilities from financial institutions, management believes that the Group will have sufficient funds from its operations to meet its financial obligations as and when they fall due.

Statement of Cash Flow

4Q2019

Net cash flows generated from operating activities of S\$8.2 million for 4Q2019 arose mainly from the operating profit before working capital changes of S\$6.7 million and inflow of working capital of S\$2.1 million, offset by income tax and interest payment of S\$0.3 million and S\$0.3 million respectively.

Net cash flows used in investing activities of S\$1.7 million for 4Q2019 were mainly attributed to the purchase of property, plant and equipment and intangible assets of S\$0.4 million and S\$0.3 million respectively, payment of deferred purchase consideration of S\$1.1 million and loans made to a joint venture of S\$0.1 million, offset by return of capital by a joint venture of S\$0.2 million.

Net cash flows used in financing activities of S\$3.9 million for 4Q2019 were mainly attributed to repayment of loans and borrowings and lease liabilities of S\$2.3 million and S\$1.6 million respectively.

FY2019

Net cash flows generated from operating activities of S\$25.7 million for FY2019 arose mainly from the operating profit before working capital changes of S\$26.8 million and inflow of working capital of S\$1.8 million, offset by income tax and interest payment of S\$1.9 million and S\$1.0 million respectively.

Net cash flows used in investing activities of S\$18.7 million for FY2019 were mainly attributed to the purchase of property, plant and equipment and intangible assets of S\$1.5 million and S\$0.6 million respectively, payment of deferred purchase consideration of S\$15.6 million, loans to associate and a joint venture of S\$0.3 million and S\$0.6 million respectively, and other investments of S\$0.4 million, offset by repayment of shareholder's loan and return of capital by a joint venture of S\$0.1 million and S\$0.2 million respectively.

Net cash flows generated from financing activities of S\$0.3 million for FY2019 arose mainly from proceeds from issuance of shares of S\$0.7 million, proceeds from Convertible Loan and loans and borrowings of S\$9.8 million and S\$3.0 million respectively, offset by dividend paid to non-controlling interests of S\$0.4 million, and repayment of loans and borrowings and lease liabilities of S\$6.9 million and S\$5.9 million respectively.

Cash and cash equivalents was S\$27.3 million as at 31 December 2019, compared to S\$20.0 million as at 31 December 2018.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Against the backdrop of a challenging 2019, the Group has performed well, executing growth initiatives despite neutral business conditions. In the near term, the Group expects to be impacted by the recent outbreak of Covid-19 as consumer discretionary spending will be affected, which in turn will affect elective medical services within the Diagnostics & Aesthetics segment. Furthermore, medical tourism, is expected to remain poor in the near term due to the Covid-19 epidemic in the region.

The Group continues with its growth initiatives in key specialist verticals such as Obstetrics and Gynaecology (“**O&G**”) and Paediatrics. Accordingly, the Group added a new gynaecologist and two new paediatricians during 4Q2019. The Group will continue to pursue organic growth through recruitment initiatives to hire more specialists in both key and complementary verticals.

Overseas, the Group will focus on its various growth strategies for its overseas market and remains optimistic on the continued growth of its joint ventures. On 7 February 2020, the Group subscribed for additional shares in CCAI to further tap into the growing market opportunities in Vietnam. The Group continues to see the potential in this synergistic investment as demonstrated by CCAI Group’s growth in revenue. Beyond its existing footprints in Singapore, Vietnam, Indonesia and Australia, the Group continues to explore new areas for growth in Vietnam, Indonesia, Cambodia, Thailand and Malaysia.

On the inorganic front, the Group continues to explore earnings accretive acquisitions in both key and complementary verticals. The Group is also leveraging on its strategic partnership with CHA Healthcare Co., Ltd., which was built upon the premise of exploring near-term projects in Vietnam, Australia, Singapore and other key Asian markets. Any material developments on future corporate actions will be announced to shareholders accordingly.

11. Dividend

(a) *Whether an interim (final) ordinary dividend has been declared (recommended); and*

Name of Dividend	:	Final Dividend
Dividend Type	:	Cash
Dividend Rate	:	0.8 cents per ordinary share
Tax Rate	:	Exempted from tax (One-tier corporate tax system)
Total Amount Payable	:	S\$3,863,000

(b) *Corresponding Period of the Immediately Preceding Financial Year*

No dividend has been declared or recommended for the corresponding period of the immediately preceding financial year.

(c) *Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).*

Refer to paragraph 11(a).

(d) *The date the dividend is payable.*

To be announced later.

(e) *The date on which Registrable Transfers received by the company (up to 5.00 p.m.) will be registered before entitlements to the dividend are determined*

To be announced later.

12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision

Not applicable.

13. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transaction as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate for interested person transactions. The aggregate value of the interested person transactions conducted in FY2018 is disclosed below.

Name of interested person	Aggregate value of all interested person transactions during the financial year under review	
	31/12/2019 S\$'000	31/12/2018 S\$'000
K S Beng Pte Ltd - Rental	188	195
MW Medical Holdings Pte Ltd - Rental	162	170
MW Medical Pte Ltd - Nursing services	4	10
CHA Healthcare Singapore Pte Ltd - Interest on Convertible Loan	202	-
TSMP Law Corporation - Professional fees	121	-

14. Negative confirmation pursuant to Rule 705(5).

Not applicable as it is not required for announcement on full year results.

15. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H of the Catalist Rules) under Rule 720(1) of the Catalist Rules.

16. Use of proceeds from the Convertible Loan

As at the date of this announcement, the net proceeds from the Convertible Loan (as defined in paragraph 1(d)(ii) of this announcement) of approximately S\$9.7 million have been utilised as follows:

<u>Use of Net Proceeds</u>	<u>Allocation of Net Proceeds</u> S\$ million	<u>Balance of unutilised Net Proceeds as at 7 February 2020 (being date of the last update)</u> S\$ million	<u>Utilisation of Net Proceeds from 8 February 2020 to the date hereof</u> S\$ million	<u>Balance of unutilised Net Proceeds as at the date hereof</u> S\$ million
(i) Merger and acquisitions	7.8	7.0	-	7.0
(ii) General business purposes	1.9	1.9	-	1.9
	9.7	8.9	-	8.9

The above use of proceeds is in accordance with the intended use as stated in the announcement relating to the Convertible Loan.

PART II – ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT

17. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer’s most recently audited annual financial statements, with comparative information for the immediately preceding year.

2018	Health	Diagnostic & Aesthetics	Others	Adjustment and Elimination	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue:					
External customers	62,766	31,803	103	-	94,672
Inter-segment	24	1,261	624	(1,909)	-
Total revenue	62,790	33,064	727	(1,909)	94,672
Segment results:					
Segment gross profit ⁵	26,737	16,424	488	(408)	43,241
Depreciation and amortisation ⁶	(860)	(2,481)	(785)	-	(4,126)
(Loss)/Gain on disposal of property, plant and equipment	(4)	21	(5)	-	12
Share based compensation	-	-	(390)	-	(390)
Gain on dilution of interest in joint venture	29	-	-	-	29
Impairment of trade receivables	(45)	(102)	-	-	(147)
Financial income	6	13	81	-	100
Interest expenses	(542)	(87)	(305)	-	(934)
Amortisation of loan costs	(45)	-	-	-	(45)
Accretion of interest on deferred purchase consideration	(115)	-	-	-	(115)
Accretion of interest on lease liabilities	(83)	(115)	(112)	-	(310)
Share of result of joint ventures and associates	(105)	378	-	-	273
Unallocated expenses, net					(21,519)
Profit before tax					16,069
2017					
Revenue:					
External customers	60,129	24,368	572	-	85,069
Inter-segment	100	1,400	421	(1,921)	-
Total revenue	60,229	25,768	993	(1,921)	85,069
Segment results:					
Segment gross profit	24,149	13,305	762	(421)	37,795
Depreciation and amortisation	(987)	(2,288)	(687)	-	(3,962)
Gain/(Loss) on disposal of property, plant and equipment	23	1	(1)	-	23
Share based compensation	-	-	(324)	-	(324)
Reversal of impairment loss on investment in joint venture	-	167	-	-	167
Impairment of trade receivables	(21)	(46)	-	-	(67)
Financial income	-	-	71	-	71
Interest expenses	(585)	(142)	(70)	-	(797)
Amortisation of loan costs	(45)	-	-	-	(45)
Accretion of interest on deferred purchase consideration	(258)	-	-	-	(258)
Share of result of joint ventures and associate	(120)	176	-	-	56
Unallocated expenses, net					(18,555)
Profit before tax					14,104

⁵ Included in segment gross profit is depreciation of right-of-use assets of S\$5,052,000 relating to right of use of leased premises of which S\$1,209,000, S\$1,342,000 and S\$2,501,000 are allocated to Health, Diagnostic & Aesthetics and Others segment respectively.

⁶ Included in depreciation and amortisation is depreciation of right-of-use assets of S\$872,000 relating to right of use of medical equipment (i.e. assets under hire purchase) of which S\$683,000 and S\$189,000 are allocated to Diagnostics & Aesthetics and Others segment respectively.

18. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the operating segments.

Refer to paragraph 8 for further details.

19. A breakdown of sales

	Group			
	FY2019	FY2018	Increase/(decrease)	
	S\$'000	S\$'000	S\$'000	%
Sales reported for first half year	44,643	40,824	3,819	9.4
Operating profit after tax before deducting minority interest for first half year	6,832	6,910	(78)	(1.1)
Sales reported for second half year	50,029	44,245	5,784	13.1
Operating profit after tax before deducting minority interest for second half year	6,803	6,005	798	13.3

20. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:-

	Latest Full Year S\$'000	Previous Full Year S\$'000
Ordinary ⁴	3,863	-
Total	3,863	-

⁴ Total annual dividend for FY2019 comprises recommended FY2019 final dividend of S\$3,863,000.

21. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10). If there are no such persons, the issuer must make an appropriate statement.

The information pursuant to Rule 704(10) on persons occupying managerial positions in the Company or any of its principal subsidiaries who are related to a director or chief executive officer or substantial shareholder of the Company is as follows:

Name	Age	Remuneration/ Professional fees (S\$'000)	Family relationship with any director and/or substantial shareholder	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Dr Jimmy Beng Keng Siew	76	258 ^(a)	Father of Dr Beng Teck Liang (Executive Director and Chief Executive Officer)	Medical Director of the urology practice Responsible for performing clinical duties associated with the urology practice and attending to patients since 2014.	None

Note:

(a) The professional fee paid is on a fee sharing basis as provided in the agreement between the Group and Dr Jimmy Beng.

BY ORDER OF THE BOARD

Dr Beng Teck Liang
Chief Executive Officer
24 February 2020

*This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("**Sponsor**") in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.